The Latest Analyst Ratings for PerkinElmer
Within the last quarter, PerkinElmer (NYSE:PKI) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Barclays Maintains Equal-Weight on PerkinElmer, Lowers Price Target to $140
Barclays analyst Luke Sergott maintains PerkinElmer (NYSE:PKI) with a Equal-Weight and lowers the price target from $145 to $140.
Benzinga’s Top Ratings Upgrades, Downgrades For December 12, 2022
Upgrades For Colliers International Group Inc (NASDAQ:CIGI), Goldman Sachs upgraded the previous rating of Neutral to Buy. Colliers…
Citigroup Upgrades PerkinElmer to Buy, Announces $170 Price Target
Citigroup analyst Patrick Donnelly upgrades PerkinElmer (NYSE:PKI) from Neutral to Buy and announces $170 price target.
JPMorgan To Rally Around 17%? Here Are 10 Other Price Target Changes For Tuesday
Morgan Stanley raised JPMorgan Chase & Co. (NYSE:JPM) price target from $126 to $153. . Morgan Stanley analyst…
5 Analysts Have This to Say About PerkinElmer
PerkinElmer (NYSE:PKI) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Cowen & Co. Upgrades PerkinElmer to Outperform, Lowers Price Target to $164
Cowen & Co. analyst Max Masucci upgrades PerkinElmer (NYSE:PKI) from Market Perform to Outperform and lowers the price target from $192 to $164.
Barclays Upgrades PerkinElmer to Equal-Weight, Raises Price Target to $145
Barclays analyst Luke Sergott upgrades PerkinElmer (NYSE:PKI) from Underweight to Equal-Weight and raises the price target from $130 to $145.
PerkinElmer Launches Ready-to-use Adeno-associated Virus Vectors Detection Kits To Support Researchers Working On Gene Therapies
PerkinElmer, Inc., (NYSE:PKI), a global leader committed to innovating for a healthier world, today launched ready-to-use Adeno-associated Virus Vectors (AAV) Detection Kits to support researchers working on
Credit Suisse Maintains Neutral on PerkinElmer, Lowers Price Target to $160
Credit Suisse analyst Dan Leonard maintains PerkinElmer (NYSE:PKI) with a Neutral and lowers the price target from $175 to $160.